Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Theratechnologies Inc T.TH

Alternate Symbol(s):  THTX

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. It blocks viral entry into host cells while preserving normal immunologic function. The Company is also investigating an intramuscular method of administration of Trogarzo. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy.


TSX:TH - Post by User

Comment by PWIB123on Nov 21, 2022 5:25pm
75 Views
Post# 35116936

RE:Merck AG initially bought US rights from Th

RE:Merck AG initially bought US rights from ThWow!  You're memory is long.  What was teh difference in this Ph. 3 trial versus what they are attempting to do today?  

Biobob wrote:  

Merck KGaA finds value in Theratechnologies

 

Merck KGaA has come to the rescue of Theratechnologies, buying US rights to Tesamorelin, in phase III trials as a treatment for excess abdominal fat in HIV patients with lipodystrophy, in a deal worth up to $215m.

Phase III data on the product released so far has been disappointing, leading to predictions that the company would struggle to sign up a top tier pharmaceutical company; a prediction that appears to have come true (Tesamorelin data reduces options for Theratechnologies, June 23, 2008). Even so, the underwhelming response from investors was surprising, with the stock edging just 7% higher to C$2.35 in early trade.




<< Previous
Bullboard Posts
Next >>